All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2018-04-27T14:00:02.000Z

Voxtalisib shows promising efficacy in R/R FL but not for other iNHL and CLL

Apr 27, 2018
Share:

Bookmark this article

A phase II non-randomized, open-label trial (NCT01403636) assessed the safety and efficacy of voxtalisib (XL765/SAR245409) in patients with specific lymphoma subtypes or leukemia. Voxtalisib is a reversible inhibitor of phosphoinositide-3 kinase (PI3K) and a weak inhibitor of the mammalian target of rapamycin (mTOR). The study by Jennifer Brown, medical oncologist at the Dana-Farber Cancer Institute, Boston, was published by The Lancet Haematology online on 14 March 2018.

Study Overview

  • Patients were enrolled from 30 oncology clinics in USA, Europe and Australia
  • Total number of patients (N = 167) enrolled in the study were diagnosed with relapsed or refractory (R/R); mantle cell lymphoma (MCL) n = 42, follicular lymphoma (FL) n = 47, diffuse large B-cell lymphoma (DLBCL) n = 42 and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) n = 36
  • Patients received 50 mg oral voxtalisib twice daily in 28-day continuous cycles until disease progression or unacceptable toxicity
  • The primary endpoint of the study was overall response rate (ORR) for each of the disease subtypes. Secondary endpoints included progression-free survival (PFS), duration of response (DOR) and safety

Key Findings

  • Median follow-up for all patients = 16.4 weeks
  • ORR for each subtype:
    • MCL = 11.9% (95% CI, 4.0–25.6%)
      • Complete response (CR) = 7.1% and partial response (PR) = 4.8%
    • FL = 41.3% (95% CI, 27.0–56.8%)
      • CR = 10.9% and PR = 30.4%
    • DLBCL = 4.9% (95% CI, 0.6–16.5%)
      • CR = 0% and PR = 4.9%
    • CLL/SLL = 11.4% (95% CI, 3.2–26.7%)
      • CR = 0% and PR = 11.4%
    • Median PFS for each subtype:
      • MCL = 8.9 weeks (95% CI, 7.86–12.86)
      • FL = 58.0 weeks (95% CI, 26.00–not calculated)
      • DLBCL = 7.1 weeks (95% CI, 5.14–8.14)
    • CLL/SLL = 24.1 weeks (95% CI, 16.57–31.57

Safety

  • Most common adverse events grade ≥3:
    • Anemia n = 21 (13%), pneumonia n = 15 (9%), fatigue n = 10 (6%) and diarrhea n = 5 (3%)
    • 53 patient deaths were reported (32%), 43 deaths were due to disease progression and 8 due to adverse events considered unrelated to the study

From the results, voxtalisib demonstrated some promising efficacy in FL but not in the other lymphoma subtypes or CLL. The authors noted that voxtalisib had an acceptable safety profile and that it might therefore warrant further its study for the FL subtype.

  1. Brown JR. et al. Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukemia: an open-label, phase 2 trial. The Lancet Haematology. 2018 Apr;5(4): e170-e180. doi: 10.1016/S2352-3026(18)30030-9. Epub 2018 Mar 14.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox